Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group: Bevacizumab for Stromal Ovarian Tumors
Jubilee BrownWilliam E. BradyJulian C. SchinkLinda Van LeMario M. LeitaoS. Diane YamadaKoen De GeestDavid M. Gershenson
0
Citation
0
Reference
10
Related Paper
Keywords:
Gynecologic oncology
Group B
Cite
Citations (4)
Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metastatic colorectal cancer in recent years has increased from 5 months with best supportive care to nearly 2 years with chemotherapy combined with bevacizumab, an antivascular endothelial growth factor monoclonal antibody. New prognostic and predictive biomarkers have been identified to guide chemotherapy in metastatic colorectal cancer, such as KRAS and BRAF oncogenes. However, the status of these oncogenes does not affect the efficacy of bevacizumab, and biomarkers predicting response to treatment with bevacizumab are still lacking. Addition of bevacizumab to regimens based on fluoropyrimidines or irinotecan has been shown to improve overall survival in treatment-naïve patients with metastatic colorectal cancer. Similarly, a significant increase in overall survival rate is achieved by adding bevacizumab to fluoropyrimidines and oxaliplatin in patients with disease progression. Bevacizumab has been found to be effective even when used as third-line therapy and later. In addition, cohort studies have shown that bevacizumab improves survival significantly despite disease progression. Finally, bevacizumab therapy in the neoadjuvant setting for the treatment of liver metastasis is well tolerated, safe, and effective.
Cite
Citations (8)
有 bevacizumab 的治疗，一个 antiangiogenic 代理人，在病人与变形或 unresectable colorectal 癌症不到 4 年以前在日本被同意。Bevacizumab 与变形 colorectal 癌症改进病人的幸存；然而，它可以导致象流血那样的复杂并发症，它有时是致命的。因为治疗的潜在的风险超过它的好处， Bevacizumab 应该仅仅在小心的考虑以后被管理。因此，药品的公司不与大脑转移为病人推荐 bevacizumab 治疗。当一些报告支持 bevacizumab 的小心的使用时，其它报导与转移在病人禁止它的使用到中央神经系统(CNS ) 不总是是必要的，包括大脑。因此，在有大脑转移的 colorectal 癌症病人的 bevacizumab 治疗是争论的，并且大脑转移是否在反脉管的 endothelial 生长期间是为 intracranial 出血的一个风险因素，是不清楚的因素(VEGF ) 治疗。没有大脑转移，我们与周期性的 colorectal 癌症报导一个 65 岁的人和一个 65 岁的人；分别地，这些病人在 bevacizumab 的管理以后开发了 multifocal 和独居的 intracranial 出血。我们的调查结果建议就算病人没在 bevacizumab 治疗以前有大脑转移并且也建议大脑转移不是为有 bevacizumab 治疗的 intracranial 出血的一个风险因素，那 intracranial 出血能发生。这些调查结果也询问在 anti-VEGF 上从临床的试用与大脑转移排除病人的必要性治疗。
Intracranial tumor
Cite
Citations (0)
Taxane
Progression-free survival
Cite
Citations (13)
Group B
Cite
Citations (0)
The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC). However, there remains a need for reproducible, validated, inexpensive and accessible prognostic markers to aid treatment selection. The optimal treatment duration and the role of bevacizumab in certain patient subgroups, considered at particular risk of bevacizumab-mediated toxicity, also require further investigation. The aim of the ASCENT study [an Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™)] is to evaluate the relationship between the host inflammatory response as measured by neutrophil/lymphocyte ratio (NLR) and treatment outcomes in patients with previously untreated mCRC receiving bevacizumab-based first- and second-line treatment. This open-label, prospective, single arm, phase IV, Australian multi-centre study evaluates the relationship between the host inflammatory response as measured by NLR and treatment outcomes in patients with previously untreated mCRC receiving bevacizumab-based first- and second-line treatment. 150 patients will be recruited from 16 centres around Australia. Patients will receive trial treatments in two phases: Phase A: XELOX or mFOLFOX6 plus bevacizumab administered from study start until first disease progression; and Phase B: FOLFIRI plus bevacizumab administered from first disease progression until second disease progression. The primary analysis will test the association between NLR and progression free survival using a proportional Hazards Model. Secondary analyses will investigate whether the relationship can be improved upon with other prognostic biomarkers, and further characterise the safety of bevacizumab following treatment initiation, and when continued after progression in combination with standard chemotherapy regimens (presented through summary statistics and Kaplan Meier curves). Quantifying the relationship between NLR and PFS will inform decision making on the extent to which this simple metric may be applied clinically. ClinicalTrials.gov: NCT01588990
FOLFIRI
Cite
Citations (18)
Progression-free survival
Cite
Citations (90)
Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We sought to conduct a meta-analysis to assess the benefits of bevacizumab with chemotherapy and to identify the ideal chemotherapy partner of bevacizumab in the first-line setting for HER2-negative advanced breast cancer patients.Computerized and manual searches were performed to identify randomized clinical trials evaluating the efficacy of bevacizumab plus chemotherapy versus chemotherapy alone or bevacizumab with different chemotherapy regimens as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer patients. Risk ratios or odds ratios with their 95% CIs were used to estimate the association between multiple combinations of bevacizumab with chemotherapy and various clinical outcomes.With 7 trials identified, this analysis included 3,984 eligible patients. The addition of bevacizumab to chemotherapy resulted in a statistically significant improvement in PFS (P=0.019) and objective response rate (ORR; P<0.001) rather than in OS (P=0.783) when compared with chemotherapy alone. The greater benefits in PFS and ORR were achieved from bevacizumab plus taxane-based regimens compared with bevacizumab plus capecitabine-based regimens, while bevacizumab plus capecitabine had comparable OS with bevacizumab plus paclitaxel. Additionally, bevacizumab-based triplet therapy failed to improve the clinical outcomes when compared with doublet therapy.This meta-analysis reveals that the addition of bevacizumab to chemotherapy yielded PFS and ORR benefits in HER2-negative advanced breast cancer. Additional studies are still prompted to further optimize the first-line treatment of bevacizumab.
Taxane
Cite
Citations (6)
Surgical oncology
Refractory (planetary science)
Cite
Citations (31)
Gynecologic oncology
Nomogram
Cite
Citations (0)